Compare Bilibili Inc (BILI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Bilibili Inc trades at $17.73 (market cap $7.65B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 17.5× Bilibili Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | VRTX | |
|---|---|---|
Market Cap | $7.65B | $134.25B |
Sector | Media | Health |
52-Week High | $35.92 | $529.65 |
52-Week Low | $15.96 | $376.62 |
Enterprise Value | $5.49B | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
